HB3168 creates the Retail Sale of Tianeptine Prohibition Act. Beginning January 1, 2026, it would make it unlawful in Illinois for any person to sell, offer to sell, or distribute any product containing tianeptine. The bill includes an exception for tianeptine that is lawfully dispensed or prescribed by a pharmacist or other health care professional, so the prohibition is aimed at retail and consumer-market products rather than regulated medical use.
The bill also defines “health care professional” broadly to include persons who treat human ailments and are subject to state licensure or regulation, including students and residents. A violation would be treated as a business offense and carry a minimum fine of $1,500 for each violation. The act would take effect January 1, 2026, and would add a new chapter of state law focused specifically on tianeptine sales.
Impact
If enacted, HB3168 would create a new Illinois statutory prohibition on the retail sale and distribution of tianeptine-containing products, effectively removing such products from general consumer commerce in the state except where dispensed or prescribed through licensed medical channels. It would establish a new enforcement mechanism through business-offense penalties and mandatory minimum fines, giving state and local authorities a clear basis to cite sellers, distributors, and retailers of prohibited products.
Sentiment
Based on the bill text and the absence of recorded committee testimony or votes in the provided materials, the bill appears to be framed as a public-safety and consumer-protection measure rather than a controversial policy expansion. The sponsor’s approach suggests concern about the availability of tianeptine in retail products and a desire to restrict nonmedical access. Because there is no transcript or voting history here, there is no documented opposition or support to gauge legislative sentiment beyond the bill’s protective intent.
Contention
The main point of potential contention is the breadth of the ban on all retail sales and distribution of tianeptine products, which could affect convenience stores, smoke shops, supplement retailers, and online sellers. Another possible issue is the scope of the exception for products prescribed or dispensed by a pharmacist or health care professional, including how broadly “health care professional” is defined and whether that could create ambiguity in enforcement. Stakeholders concerned about access, regulatory burden, or the treatment of products with legitimate medical use may object, while public-health advocates are likely to support the restriction.